Fresenius Kabi Introduces Simplist™ Heparin Sodium Injection, USP, Expanding Portfolio of Ready-to-Administer Prefilled Syringes

LAKE ZURICH, Ill., December 15, 2016 – Fresenius Kabi announced today the immediate availability in the United States of Heparin Sodium Injection (5,000 USP units per mL) in the company’s Simplist™ ready-to-administer prefilled syringe.

Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

Fresenius Kabi offers U.S. customers a broad range of Heparin presentations which now includes the Heparin 5,000 USP units per mL ready-to-administer prefilled syringe for subcutaneous and intravenous bolus injections.

“Delivering the right drug at the right dose is always important, particularly with High-Alert medications such as Heparin,” said John Ducker, president and chief executive officer of Fresenius Kabi USA. “Fresenius Kabi Simplist ready-to-administer prefilled syringes help promote safe practices and can minimize medication errors by reducing drug preparation steps and vial-to-syringe transfers.”

All Simplist ready-to-administer prefilled syringes, including the new Heparin presentation, are designed to offer clear and consistent labeling, individual bar coding on both packaging and syringes, require no assembly or point-of-care preparation and have a 24-month shelf life.

According to the Institute for Safe Medication Practices (ISMP), High-Alert medications are defined as “drugs that bear a heightened risk of causing significant patient harm when they are used in error. Although mistakes may or may not be more common with these drugs, the consequences of an error are clearly more devastating to patients.”

For full prescribing information, including more information about all the Simplist ready-to-administer prefilled syringes exclusively from Fresenius Kabi, please visit www.simplist-us.com.

About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany.

Media Contact
Fresenius Kabi
Matt Kuhn
847-550-5751
matt.kuhn@fresenius-kabi.com